TG Therapeutics Logo Image

TG Therapeutics

TG Therapeutics has reached its limit for report views.

Please check back to see if TG Therapeutics has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.

Most Recent Annual Report

2016 Annual Report and Form 10K

TG Therapeutics

TG Therapeutics does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



Archived Annual Reports

About TG Therapeutics

11-50 Employees
Based in New York, New York

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes.

Ticker:
TGTX
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol